Special Issue

Topic: Organ Dysfunction in Metabolic-Associated Fatty Liver Disease: Effect of Cofactors

A Special Issue of Metabolism and Target Organ Damage

ISSN 2769-6375 (Online)

Submission deadline: 31 Jul 2024

Guest Editors

Kusum K. Kharbanda, PhD

Department of Internal Medicine, University Nebraska Medical Center, Veteran Affairs Medical Center, Omaha, NE, USA.

Ashwani K. Singal, MD

Sanford School of Medicine, University of South Dakota, Vermillion, SD, USA.

Amedeo Lonardo, MD

Department of Internal Medicine, Ospedale Civile di Baggiovara, Modena, Italy.

Natalia A. Osna, MD, PhD

Department of Internal Medicine, University of Nebraska Medical Center, Veteran Affairs Medical Center, Omaha, NE, USA.

Special Issue Introduction

Nonalcoholic fatty liver disease (NAFLD), now tendentially renamed MAFLD (metabolic-associated fatty liver disease), is a systemic metabolic disorder that encompasses a clinico-pathological spectrum ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma.

NAFLD and NASH are pathogenically associated with gut dysbiosis, sarcopenia and expanded, dysfunctional adipose tissue. Clinically, extra-hepatic manifestations, notably either the full-blown metabolic syndrome or its individual components and cardio-nephro-vascular complications, are major features of MAFLD and dictate the disease course.

This thematic Special Issue highlights metabolic syndrome co-factors, including but not limited to alcohol, diet, immune surveillance, infection, genetics, epifactors and sedentary behavior, which affect liver disease progression and also induce dysfunction in other target organs and organ systems such as gastrointestinal, cardiovascular, adipose, muscle, kidneys and pancreas.

Original research, review articles, and short communications on the role of co-factors exacerbating organ dysfunction in MAFLD are welcome to this topical Special Issue.